Denmark announced that he did not bring Johnson & Johnson's Vaccine Covid-19 into the national vaccination program because of concerns of blood-freezing.

"The Danish Health Authority concluded that Jonson & Johnson's benefits of Jonson & Johnson's vaccine was not greater than the risk of side effects in vaccines," Danish authorities today announced.

"Therefore, the Danish Health Authority will continue the Covid-19 vaccination program without using Johnson & Johnson's vaccines".

Johnson & Johnson's Covid-19 vaccine in ZNA Middelheim Hospital in Antwerp, Belgium, on April 30.

This move took place after this Northern Nation last last month stopped using Astrazeneca's vaccine because of concerns about rare blood clotting complications.

The implementation of Johnson & Johnson vaccine is also delayed in other European countries due to similar concerns about the clotting complications, whether the World Health Organization (WHO) and the European Pharmaceutical Agency (EMA)

EMA's Safety Commission on April 20 concluded that "warning about the occurrence of abnormal blood blood clots and low blood platelet levels should be added to the product information" of Vaccine Johnson & Johnson but think still

The removal of Johnson & Johnson vaccine, which accounts for about one-third of the Covid-19 vaccine supply under Denmark, can significantly delay the country's vaccination plan.